Novo Nordisk A/S ADR buy The Goldman Sachs Group, Inc.
Start price
30.05.24
/
50%
€123.00
Target price
30.05.25
€144.02
Performance (%)
-49.11%
End price
31.05.25
€62.60
Summary
This prediction ended on 31.05.25 with a price of €62.60. Massive losses of -49.11% were the result for the BUY prediction by The_Goldman_Sachs_Gr. The_Goldman_Sachs_Gr has a follow-up prediction for Novo Nordisk A/S ADR where he still thinks Novo Nordisk A/S ADR is a Buy. Dividends of €1.56 are taken into consideration when calculating the performance. The_Goldman_Sachs_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Novo Nordisk A/S ADR | 6.676% | 6.676% | -3.615% |
| iShares Core DAX® | 1,01 % | 2,70 % | 4,36 % |
| iShares Nasdaq 100 | -6,47 % | -8,77 % | 18,00 % |
| iShares Nikkei 225® | -6,52 % | -12,58 % | 40,91 % |
| iShares S&P 500 | -2,72 % | -1,75 % | 16,97 % |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Novo Nordisk A/S ADR diskutieren
Novo Nordisk A/S (NYSE: NVO) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $156.00 price target on the stock.
Ratings data for NVO provided by MarketBeat
In the thread Trading Novo Nordisk A/S ADR
Die von The_Goldman_Sachs_Gr gewählte maximale Laufzeit wurde überschritten